Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$14.53 USD
-0.16 (-1.09%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $14.49 -0.04 (-0.28%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Brokerage Reports
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 1 - 20 ( 729 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Reports of Exparel Death Have Been Greatly Exaggerated; Reiterate Buy Here; PT to $39
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Gx Exparel Approval Is a Step in the Process; We Still Expect Long Brand Exclusivity; Buy on Weakness
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Solid Start to Year; New Share Buyback; Expect Near Term Exparel Duration Clarity; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Expect Meaningful Multiple Expansion in 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q4/FY23: Laying the Foundation for EXPAREL Growth Ahead of NOPAIN
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department